MGNX supply chain intelligence for MacroGenics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SAGARD-HEALTHCARE-PARTNERS | SAGARD-HEALTHCARE-PARTNERS | 92% | On May 1, 2026, MacroGenics, Inc. (the 'Company') and an entity affiliated with Sagard Healthcare Partners ('Sagard') entered into a First Amendment to the Purchase and Sale Agreement, dated as of Ju… |
| INCY | Incyte Corporation | 90% | the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agreement”), with Incyte Corporation |
| INCY | Incyte Corporation | 90% | Reciprocal relationship from INCY graph: Reciprocal relationship from MGNX graph: the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agree… |
| MILLIPORE-SIGMA | MILLIPORE-SIGMA | 90% | We also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates. |
| SIMTRA-BIOPHARMA-SOLUTIONS | SIMTRA-BIOPHARMA-SOLUTIONS | 90% | we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPha… |
| STERLING | STERLING | 90% | We also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates. |
| SYMBIOSIS | SYMBIOSIS | 90% | we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPha… |
| SYNAFFIX | SYNAFFIX | 90% | We also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates. |
| BORA | BORA | 85% | Bora will be required to provide certain clinical manufacturing and supply services to the Company |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from MGNX graph: t and future product candidates. Most of the principal materials we use in our manufacturing operations are available … |
| AZN | AstraZeneca PLC | 72% | t and future product candidates. Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally f… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX g… |
| BNTX | BioNTech SE | 72% | t and future product candidates. Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally f… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | lations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve … |
| GNMSF | Genmab A/S | 72% | Reciprocal relationship from GNMSF graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in … |
| GNMSF | Genmab A/S | 72% | Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Further, several companies are also developin… |
| JNJ | Johnson & Johnson | 72% | Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Further, several companies are also developin… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from JNJ grap… |
| LLY | Eli Lilly and Company | 72% | Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Further, several companies are also developin… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have signific… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have signific… |
| MRK | Merck & Co., Inc. | 72% | Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Further, several companies are also developin… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have signifi… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Further, several companies are also developin… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX graph: for these arrangements is either based on an analogy to other accounting literature or an accounting policy election… |
| SNYNF | Sanofi | 72% | for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement th… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BORAY | Bora Pharmaceuticals Co., Ltd. | 95% | pany will be added to the Aggregate Purchase Price for purposes of calculating the royalty payment cap. Asset Purchase Agreement On May 11, 2026, the Company entered into an Asset Purchase Agreement … |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 95% | Reciprocal relationship from BORAY graph: Reciprocal relationship from MGNX graph: pany will be added to the Aggregate Purchase Price for purposes of calculating the royalty payment cap. Asset Purcha… |
| INCYTE | INCYTE | 95% | In January 2022, we entered into an agreement with Incyte to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period. |
| TERSERA | TERSERA | 92% | We commercially produce MARGENZA and ZYNYZ for TerSera and Incyte, respectively. |
| INCY | Incyte Corporation | 90% | Reciprocal relationship from INCY graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from INCY graph: Reciprocal relationship from MGNX graph: the Company previously sold to Saga… |
| INCY | Incyte Corporation | 90% | the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) under the Company's Global Collaboration and License Agreement dated as of Octobe… |
| CAH | Cardinal Health, Inc. | 85% | es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately … |
| CAH | Cardinal Health, Inc. | 85% | Reciprocal relationship from CAH graph: Reciprocal relationship from MGNX graph: es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is depende… |
| MCK | McKesson Corporation | 85% | Reciprocal relationship from MCK graph: Reciprocal relationship from MGNX graph: rnment agencies of high credit standing. The Company's revenue relates to contract development and manufacturing servi… |
| MCKESSON-SPECIALTY-CARE-DISTRIBUTION-LLC | MCKESSON-SPECIALTY-CARE-DISTRIBUTION-LLC | 85% | rnment agencies of high credit standing. The Company's revenue relates to contract development and manufacturing services, agreements with various collaborators, and MARGENZA net product sales (prior… |
| SNYNF | Sanofi | 85% | IELD in November 2022, and the Company recognized $ million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amend… |
| SNYNF | Sanofi | 85% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX graph: IELD in November 2022, and the Co… |
| TERSERA-THERAPEUTICS-LLC | TERSERA-THERAPEUTICS-LLC | 85% | rnment agencies of high credit standing. The Company's revenue relates to contract development and manufacturing services, agreements with various collaborators, and MARGENZA net product sales (prior… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical … |
| AZN | AstraZeneca PLC | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| BNTX | BioNTech SE | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX g… |
| GILD | Gilead Sciences, Inc. | 72% | perations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, fin… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX graph: perations. Recent tax reforms in th… |
| JNJ | Johnson & Johnson | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical … |
| LLY | Eli Lilly and Company | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from LLY grap… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conducted clinical studies of MGD014 and MGD020 … |
| ZLAB | Zai Lab Limited | 72% | es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately … |
| ZLAB | Zai Lab Limited | 72% | Reciprocal relationship from ZLAB graph: Reciprocal relationship from MGNX graph: es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is depend… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MGNX-DEBT | Debt stack $36.5M | 90% | Market cache reports total debt of $36.5M. |
| MGNX-DEBT-10957 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2013-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MGNX-OWNER-ARMISTICE-CAPITAL-LLC | ARMISTICE CAPITAL, LLC | 90% | 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 112 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 |